CN109316509A - Relieving cough and reducing sputum oral solution and preparation method thereof - Google Patents
Relieving cough and reducing sputum oral solution and preparation method thereof Download PDFInfo
- Publication number
- CN109316509A CN109316509A CN201811301663.1A CN201811301663A CN109316509A CN 109316509 A CN109316509 A CN 109316509A CN 201811301663 A CN201811301663 A CN 201811301663A CN 109316509 A CN109316509 A CN 109316509A
- Authority
- CN
- China
- Prior art keywords
- parts
- relieving cough
- reducing sputum
- oral solution
- liquorice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 67
- 206010036790 Productive cough Diseases 0.000 title claims abstract description 58
- 208000024794 sputum Diseases 0.000 title claims abstract description 51
- 210000003802 sputum Anatomy 0.000 title claims abstract description 51
- 229940100688 oral solution Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 53
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000007788 liquid Substances 0.000 claims abstract description 28
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 25
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 24
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 23
- 235000011477 liquorice Nutrition 0.000 claims abstract description 23
- 239000008414 paregoric Substances 0.000 claims abstract description 22
- 229940069533 paregoric Drugs 0.000 claims abstract description 22
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000012153 distilled water Substances 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 5
- 241000723346 Cinnamomum camphora Species 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 229960000846 camphor Drugs 0.000 claims description 5
- 229930008380 camphor Natural products 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 229940050957 opium tincture Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229940098465 tincture Drugs 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 11
- 239000000047 product Substances 0.000 description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002555 auscultation Methods 0.000 description 4
- 229940045348 brown mixture Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- IIQJBVZYLIIMND-UHFFFAOYSA-J potassium;antimony(3+);2,3-dihydroxybutanedioate Chemical compound [K+].[Sb+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O IIQJBVZYLIIMND-UHFFFAOYSA-J 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000004176 ammonification Methods 0.000 description 2
- 229910052787 antimony Inorganic materials 0.000 description 2
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GLVPUAWFPNGKHO-UHFFFAOYSA-L N.[Fe+2].[O-]S([O-])(=O)=O Chemical compound N.[Fe+2].[O-]S([O-])(=O)=O GLVPUAWFPNGKHO-UHFFFAOYSA-L 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- RSJOBNMOMQFPKQ-ZVGUSBNCSA-L copper;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O RSJOBNMOMQFPKQ-ZVGUSBNCSA-L 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of relieving cough and reducing sputum oral solutions and preparation method thereof.Its raw material includes: 40-60 parts of ammonium chloride, 100-130 parts of liquid extract of liquorice, 3-8 parts of guaiacol glycerol ether, 100-130 parts of paregoric, 100-130 parts of glycerol in parts by weight for this is relieving cough and reducing sputum oral solution.Preparation method includes: that ammonium chloride is taken to be dissolved in the distilled water of 10-15 times of weight according to the ratio, adjusts pH to 8-9 with liquor ammoniae dilutus；Glycerol, liquid extract of liquorice are added thereto, is uniformly mixed；Guaiacol glycerol ether aqueous solution is added, with adding with stirring；Then paregoric is added, is eventually adding distilled water or purified water to total amount, stir evenly to get.The present invention is relieving cough and reducing sputum, and oral solution not only can quickly and effectively alleviate symptom, cure patient, but also have effects that prevent recurrence.
Description
Technical field
The present invention relates to a kind of relieving cough and reducing sputum oral solutions and preparation method thereof.
Background technique
Phlegm-heat cough is evil criminal's air flue, lung mistake a surname is respectful and phlegm-heat accumulated in the lung is caused to demonstrate,prove patient, if table heresy, which does not solve, simultaneous to be shown in Table disease.Face
Bed shows as that cough, phlegm Huang is thick, coughs up and spits not well, and nasal obstruction flows turbid tears, sore throat sound dumb, red tongue body, moss thin yellow or greasy, slippery and rapid pulse；West
Doctor is diagnosed as bronchitis, suffer from cold infection or contact history more, auscultation of lung audible and dry, moist rale.Patient's ceaselessly cough
It coughs and issues allophone, not only itself feel bad exception, but also seriously affect the life of people around.
Traditional treatment cough generally uses cough syrup, but such drug has dependence, should not apply in a short time
It is more, easily cause the side effects such as tachycardia.Existing drug type is mostly antibiotic, can neither effectively eradicate cough, is also easily produced
Raw drug resistance.Brown mixture is larger to heart, liver renal toxicity because containing potassium antimony tartrate, and is easy in alkaline environment
It is transformed into bigger two antimony of tri-chlorination of toxicity.
Summary of the invention
It, not only can be with to overcome the shortcomings of the existing technology, the present invention provides a kind of relieving cough and reducing sputum oral solution and preparation method thereof
Quickly and effectively alleviate symptom, cure patient, and has effects that prevent recurrence.
Technical solution of the present invention is as follows:
A kind of relieving cough and reducing sputum oral solution, in parts by weight its raw material include:
40-60 parts of ammonium chloride,
100-130 parts of liquid extract of liquorice,
3-8 parts of guaiacol glycerol ether,
100-130 parts of paregoric,
100-130 parts of glycerol.
Preferably, the relieving cough and reducing sputum oral solution, in parts by weight its raw material include:
45-55 parts of ammonium chloride,
110-125 parts of liquid extract of liquorice,
4-6 parts of guaiacol glycerol ether,
110-125 parts of paregoric,
110-125 parts of glycerol.
Preferably, the relieving cough and reducing sputum oral solution, its raw material includes: in parts by weight
50 parts of ammonium chloride,
120 parts of liquid extract of liquorice,
5 parts of guaiacol glycerol ether,
120 parts of paregoric,
120 parts of glycerol.
Preferably, the relieving cough and reducing sputum oral solution further include: pH adjusting agent liquor ammoniae dilutus, it is further preferred that described dilute
Ammonia solution mass concentration is 10%-15%.
The relieving cough and reducing sputum oral solution further include: distilled water or purified water add to 1000 parts with distilled water or purified water.
Preferably, the relieving cough and reducing sputum oral solution pH is 8-9.
Preferably, the relieving cough and reducing sputum oral solution containing ammonium chloride (NH4Cl)4.75-5.25g/100mL。
The liquid extract of liquorice meets Chinese Pharmacopoeia regulation, can prepare by art methods, such as Chinese Pharmacopoeia method；
Also buyable commercial prod.
The paregoric is term generally in the art, is compound preparation, meets Chinese Pharmacopoeia regulation, and group is divided into often
1mL 3mg containing camphor, opium tincture 0.05mL, benzoic acid 5mg, oil of badian 0.003mL.It can be prepared by art methods, example
Such as Chinese Pharmacopoeia method；Also buyable commercial prod.
Above-mentioned relieving cough and reducing sputum oral solution is brown liquid, and taste is salty, slightly sweet.
Parts by weight of the present invention can be the unit of weight well known in the art such as μ g, mg, g, kg, be also possible to it again
Number, such as 1/10,1/100,10 times, 100 times.
The present invention also provides the preparation methods of above-mentioned relieving cough and reducing sputum oral solution, comprising: each raw material is taken according to the ratio, by ammonium chloride
It is dissolved in the distilled water of about 10-15 times weight, adjusts pH to 8-9 with liquor ammoniae dilutus (preferred mass concentration 10%)；Thereto plus
Enter glycerol, liquid extract of liquorice, is uniformly mixed；Guaiacol glycerol ether aqueous solution is added (to take guaiacol glycerol ether, add appropriate
Hot water dissolving is made), with adding with stirring；Then paregoric is added, it is (fixed to total amount to be eventually adding distilled water or purified water
Hold), stir evenly to get.
Above-mentioned preparation method further include: the Conventional procedures such as filling, sterilizing.
Relieving cough and reducing sputum oral solution prepared by the present invention is daily 3-4 times for adult recommendation taking dose, each taking
10-20mL, or follow the doctor's advice.7d is 1 course for the treatment of, can obtain significant curative effect after general 2 courses for the treatment of.
The compound preparation that relieving cough and reducing sputum oral solution of the invention is made of brown mixture (brown mixture) and ammonium chloride.
Brown mixture main component is paregoric, liquid extract of liquorice, potassium antimony tartrate etc..Since potassium antimony tartrate is to heart, liver
Renal toxicity is larger, and bigger two antimony of tri-chlorination of toxicity is readily converted into alkaline environment.It is a discovery of the invention that by antimony tartrate
Potassium replaces with guaiacol glycerol ether both and can reach better drug effect, moreover it is possible to reduce toxic side effect, improve drug safety.This
Opium contained by paregoric has antitussive effect in invention prescription, and guaiacol glycerol ether has stimulation stomach lining, reflexive
Cause bronchial secretion to increase, dilute sputum, liquid extract of liquorice has protective effect to the larynx mucous membrane of inflammation, can reduce inflammation
Caused cough.Glycerol can make medicine retention in throat and have moisten effect, play auxiliary therapeutic action to sphagitis.Ammonium chloride is logical
Stimulation oversaturation stomach lining causes mild nausea, through Vagus-pressor responses Zhi Chuanxiang maincenter, reflexive ground excitement branch gas-distribution pipe and branch gas
The glandular secretion of pipe increases, so that sputum be made to dilute, is easy to expectoration.In addition ammonium chloride has after absorbing and arranges on a small quantity through respiratory mucosa
Out and makes moisture increase in respiratory tract by osmotic pressure effect and sputum dilution is made to generate phlegm-dispelling functions.The above all medicines share can
Quick acting simultaneously maintains prolonged drug effect, to play the role of quickly relieving cough and reducing sputum and prevent recurrence.Cough-relieving of the present invention
Phlegm oral solution is clinically used for cough caused by acute respiratory inflammation, and especially phlegm is sticky is not easy expectoration person, curative for effect, effect
Significantly.
Specific embodiment
The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention..It is not specified in embodiment specific
Technology or conditions person, described technology or conditions according to the literature in the art, or carried out according to product description.It is used
Production firm person is not specified in reagent or instrument, is the conventional products that can be commercially available by regular distributor.
Liquid extract of liquorice and paregoric used below meet Chinese Pharmacopoeia regulation；Wherein, the paregoric
Every 1mL 3mg containing camphor, opium tincture 0.05mL, benzoic acid 5mg, oil of badian 0.003mL.
Embodiment 1
Relieving cough and reducing sputum oral solution, prescription:
Ammonium chloride 50g,
Liquid extract of liquorice 120mL,
Guaiacol glycerol ether 5g,
Paregoric 120mL,
Glycerol 120mL,
10% liquor ammoniae dilutus of mass concentration is appropriate,
Distilled water adds to 1000mL.
This is relieving cough and reducing sputum, and oral liquor includes: that ammonium chloride is taken to be dissolved in about 500mL distilled water according to the ratio, uses quality
PH is adjusted to 8-9 by 10% liquor ammoniae dilutus of concentration, and glycerol, liquid extract of liquorice is added, and is uniformly mixed, is added guaiacol glycerol ether
Aqueous solution (takes guaiacol glycerol ether, appropriate hot water dissolving is added to be made), with adding with stirring, finally adds paregoric, then
Add distilled water to make into 1000mL, stir evenly, packing to get.
Embodiment 2
Relieving cough and reducing sputum oral solution, prescription:
Ammonium chloride 40g,
Liquid extract of liquorice 100mL,
Guaiacol glycerol ether 3g,
Paregoric 100mL,
Glycerol 100mL,
10% liquor ammoniae dilutus of mass concentration is appropriate,
Distilled water adds to 1000mL.
This is relieving cough and reducing sputum, and oral liquor is same as Example 1.
Embodiment 3
Relieving cough and reducing sputum oral solution, prescription:
Ammonium chloride 60g,
Liquid extract of liquorice 130mL,
Guaiacol glycerol ether 8g,
Paregoric 130mL,
Glycerol 130mL,
10% liquor ammoniae dilutus of mass concentration is appropriate,
Distilled water adds to 1000mL.
This is relieving cough and reducing sputum, and oral liquor is same as Example 1.
Embodiment 4
Relieving cough and reducing sputum oral solution, prescription:
Ammonium chloride 50g,
Liquid extract of liquorice 110ml,
Guaiacol glycerol ether 3g,
Paregoric 110ml,
Glycerol 110ml,
10% liquor ammoniae dilutus of mass concentration is appropriate,
Distilled water adds to 1000ml.
Embodiment 5
Relieving cough and reducing sputum oral solution, prescription:
Ammonium chloride 50g,
Liquid extract of liquorice 130ml,
Guaiacol glycerol ether 3g,
Paregoric 130ml,
Glycerol 130ml,
10% liquor ammoniae dilutus of mass concentration is appropriate,
Distilled water adds to 1000ml.
Experimental example 1
The relieving cough and reducing sputum oral solution prepared using embodiment 1 treats 354 patients in 4 months as laboratory sample.
Treatment method: it is adult, it is 3-4 times daily, each taking 10-20mL, or follow the doctor's advice.7d is 1 course for the treatment of, 2 courses for the treatment of
After count curative effect.
Effect standard:
Recovery from illness: cough, expectoration symptom disappear, and two pulmonary respiration sounds of auscultation are clear.It is effective: cough by severe switch to it is slight or by
Moderate switchs to slightly, and expectoration symptom is significantly reduced or disappeared, and two pulmonary respiration sounds of auscultation are relatively clear or sound of vomiting sound is clearly better；Have
Effect: cough, expectoration symptom are mitigated, and two pulmonary respiration sounds of auscultation are coarse or sound of vomiting sound is improved.It is invalid: cough, expectoration symptom,
Clinical sign and x ray examination it is unchanged or aggravate.
Through counting, treatment results: the patient of recovery from illness is 148, accounts for the 41.8% of total patient；Effective 106, account for total patient
29.9%；Effective 94, account for the 26.6% of total patient；Invalid 6, account for the 1.7% of total patient；In effective and effective case
Only 2 are not cured；Total effective rate is up to 98.3%.
Typical case:
1, Wu, male 18 years old, started abscess of throat before 08,2 December in 2017, after start to cough, and abundant expectoration；
After taking this product (the relieving cough and reducing sputum oral solution of embodiment 1) 3 times, sputum is reduced, and cough mitigates, and after continuing to use 3 days, symptom is complete
It disappears, recovery from illness；
2, Liu, female, 30 years old, because flu causes coughing with a lot of sputum before 14 days, two days November in 2017, the fluid infusion 2 in clinic
After it, less effective, after this product (the relieving cough and reducing sputum oral solution of embodiment 1) 1 day, cough symptom mitigates, and sputum is reduced, and uses
After 3 days, symptom is completely disappeared, recovery from illness.
3, Liao, female, 28 years old, on January 13rd, 2018 in outpatient clinic, suffered from rhinitis throughout the year, recently, because of Changes in weather,
Cause to catch a cold, after drug therapy, cold symptoms are alleviated, and when being still coughing with a lot of sputum, take this product (1 cough-relieving of embodiment
Phlegm oral solution) after 2 days, the symptom of coughing with a lot of sputum mitigates, and continues to use, and symptom disappears after 4 days, recovery from illness.
It is attached: oral solution quality standard that the present invention is relieving cough and reducing sputum
This product containing ammonium chloride (NH4Cl it) should be 4.75%~5.25% (g/mL).
[character] this product is brown liquid, and taste is salty, slightly sweet.
[identification]
Opium alkali
(1) this product 10mL is taken, ammonification test solution is adjusted to alkalinity, and chlorination imitates 10mL, and shaking is extracted, and takes chloroform layer solution in evaporation
It in ware, is evaporated in water-bath, adds methanol 1 to drip toward residue, i.e. few drops of sulfuric acid displaing amaranths.
(2) take this product appropriate, add phosphomolybdic acid test solution and few drops of sulfuric acid, show red, after become blue.
(3) thin layer is identified: taking this product about 15mL, ammonification test solution is adjusted to alkalinity, and with chloroform 25mL, shaking is extracted, standing point
Layer (or tragacanth stirring is added to clarify emulsion layer), takes chloroform layer in evaporating dish, is evaporated in water-bath, residue adds ethyl alcohol few
Perhaps it dissolves, as test solution；Separately using opium tincture as contrast solution, is tested according to thin-layered chromatography, inhale above two solution
Each 5 μ l puts respectively on same silica gel g thin-layer plate, with diethylamine-ethyl alcohol-benzene (1: 2: 6) for solvent, after expansion, dries,
It is 10 minutes dry at 105 DEG C, it lets cool, sprays with bismuth potassium iodide solution, inspect immediately.The aobvious principal spot of test solution institute should with compare
The position of the principal spot of product solution, solid colour.
Liquid extract of liquorice
(1) this product 10mL is taken, adds dilute hydrochloric acid that glycyrrhizic acid precipitating is precipitated, filtering, precipitating is washed with water, then ammoniates test solution and make
It is dissolved, and is evaporated, and residue is pleasantly sweet, and after being dissolved in water, strength is shaken, and generates persistent foam.
(2) it takes this product 1~2 to drip, alkaline cupric tartrate test solution 1~2 is added to drip, show grass green.
[inspection] should meet mixture, and (related items provide under current edition " Chinese Pharmacopoeia " item.
[assay]
Ammonium chloride precision measures this product 2mL, sets in 50mL volumetric flask, adds water 10mL, precision plus silver nitrate solution (0.1mol/
L) 25mL adds nitric acid 1mL, adds water to scale, shakes up, filtering, discards primary filtrate, and precision measures subsequent filtrate 20mL, adds sulfuric acid
Iron ammonium indicator solution 3 drips, and is titrated to micro- red with ammonium thiocyanate liquid (0.1mol/L), makees blank with this mixture of not containing ammonium chloride
Test subtracts sample with ammonium thiocyanate liquid (0.1mol/L) ml consumed by blank titration and titrates consumed ammonium thiocyanate
Liquid (0.1mol/L) ml to get.Every 1mL silver nitrate (0.1mol/L) is equivalent to the NH of 5.349mg4Cl。
[effect and purposes] eliminating phlegm and relieving cough agent, is suitable for the diseases such as cough, more phlegm caused by a variety of causes.
100mL/ bottles of [specification].
[storage] is protected from light, and is sealed.
[validity period] 1 year.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Cause
This, these modifications or improvements, fall within the scope of the claimed invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. a kind of relieving cough and reducing sputum oral solution, which is characterized in that its raw material includes: in parts by weight
40-60 parts of ammonium chloride,
100-130 parts of liquid extract of liquorice,
3-8 parts of guaiacol glycerol ether,
100-130 parts of paregoric,
100-130 parts of glycerol.
2. relieving cough and reducing sputum oral solution according to claim 1, which is characterized in that its raw material includes: in parts by weight
45-55 parts of ammonium chloride,
110-125 parts of liquid extract of liquorice,
4-6 parts of guaiacol glycerol ether,
110-125 parts of paregoric,
110-125 parts of glycerol.
3. relieving cough and reducing sputum oral solution according to claim 1, which is characterized in that its raw material includes: in parts by weight
50 parts of ammonium chloride,
120 parts of liquid extract of liquorice,
5 parts of guaiacol glycerol ether,
120 parts of paregoric,
120 parts of glycerol.
4. relieving cough and reducing sputum oral solution according to claim 1-3, which is characterized in that the liquid extract of liquorice and multiple
Square camphor tincture meets Chinese Pharmacopoeia regulation；Wherein, the every 1mL 3mg containing camphor of the paregoric, opium tincture 0.05mL, benzene
Formic acid 5mg, oil of badian 0.003mL.
5. relieving cough and reducing sputum oral solution according to claim 1-4, which is characterized in that further include the dilute ammonia of pH adjusting agent
Solution, the liquor ammoniae dilutus mass concentration is preferably 10%-15%.
6. relieving cough and reducing sputum oral solution according to claim 1-5, which is characterized in that further include distilled water or purifying
Water adds to 1000 parts with distilled water or purified water.
7. relieving cough and reducing sputum oral solution according to claim 1-6, which is characterized in that the relieving cough and reducing sputum oral solution
PH is 8-9.
8. relieving cough and reducing sputum oral solution according to claim 1-7, which is characterized in that the relieving cough and reducing sputum oral solution
Containing ammonium chloride is 4.75-5.25g/100mL.
9. relieving cough and reducing sputum oral solution described in -8 according to claim 1, which is characterized in that its pH is 8-9, prescription are as follows:
Ammonium chloride 50g,
Liquid extract of liquorice 120mL,
Guaiacol glycerol ether 5g,
Paregoric 120mL,
Glycerol 120mL,
10% liquor ammoniae dilutus of mass concentration is appropriate,
Distilled water adds to 1000mL.
10. the preparation method of any one of the claim 1-9 relieving cough and reducing sputum oral solution characterized by comprising take according to the ratio
Ammonium chloride is dissolved in the distilled water of 10-15 times of weight by each raw material, adjusts pH to 8-9 with liquor ammoniae dilutus；It is added thereto sweet
Oil, liquid extract of liquorice are uniformly mixed；Guaiacol glycerol ether aqueous solution is added, with adding with stirring；Then compound camphor is added
Tincture is eventually adding distilled water or purified water to total amount, stir evenly to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811301663.1A CN109316509A (en) | 2018-11-02 | 2018-11-02 | Relieving cough and reducing sputum oral solution and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811301663.1A CN109316509A (en) | 2018-11-02 | 2018-11-02 | Relieving cough and reducing sputum oral solution and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109316509A true CN109316509A (en) | 2019-02-12 |
Family
ID=65259946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811301663.1A Pending CN109316509A (en) | 2018-11-02 | 2018-11-02 | Relieving cough and reducing sputum oral solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109316509A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788747A (en) * | 2004-11-05 | 2006-06-21 | 贵阳云岩西创药物科技开发有限公司 | Compound licorice root medicinal preparation and preparing method thereof |
| CN101574425A (en) * | 2008-05-05 | 2009-11-11 | 北京瑞伊人科技发展有限公司 | Child cough granule and preparation method of same |
| CN102743443A (en) * | 2012-07-13 | 2012-10-24 | 福州海王金象中药制药有限公司 | Compound glycyrrhiza oral solution preparation technology |
-
2018
- 2018-11-02 CN CN201811301663.1A patent/CN109316509A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788747A (en) * | 2004-11-05 | 2006-06-21 | 贵阳云岩西创药物科技开发有限公司 | Compound licorice root medicinal preparation and preparing method thereof |
| CN101574425A (en) * | 2008-05-05 | 2009-11-11 | 北京瑞伊人科技发展有限公司 | Child cough granule and preparation method of same |
| CN102743443A (en) * | 2012-07-13 | 2012-10-24 | 福州海王金象中药制药有限公司 | Compound glycyrrhiza oral solution preparation technology |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| King | King's American dispensatory | |
| CN107789340B (en) | Solution preparation for andrographis paniculata aerosol inhalation and preparation method thereof | |
| CN108904476A (en) | A kind of ambroxol hydrochloride aerosol inhalation solution agent and preparation method thereof | |
| US20050025823A1 (en) | Methods of use of herbal compositions | |
| CN101904850B (en) | Medicament for relieving cough and removing sputum and preparation method for syrup thereof | |
| CN101856438B (en) | Medicinal composition for treating infant asthma and preparation method and use thereof | |
| CN100518775C (en) | Medicine composition for treating cough and asthma and preparation thereof | |
| CN109316509A (en) | Relieving cough and reducing sputum oral solution and preparation method thereof | |
| CN101069688A (en) | Medicine composition containing theocin-like medicines and vitamin K | |
| CN104098491B (en) | A kind of mucolyticum acid compound and the suction acetylcysteine solution containing this compound | |
| CN114053216A (en) | A umeclidinium bromide solution preparation for inhalation and its preparation method | |
| CN101756949A (en) | Composition of ambroxol hydrochloride and cysteine and preparation method thereof | |
| KR20230127957A (en) | Pharmaceutical composition for the prevention and the treatment of respiratory deseases | |
| Jaggernauth et al. | Datura poisoning in Trinidad: a case report | |
| CN102716128A (en) | Pharmaceutical composition for treating asthma | |
| Stevens | Modern materia medica and therapeutics | |
| CN102233026B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN114344380A (en) | Asthma-relieving aerosol inhalation solution preparation and preparation method thereof | |
| Potter | A Handbook of materia medica, pharmacy and therapeutics | |
| CN103919789A (en) | Ultrasonic atomization steam inhalation treatment method of ephedrine composition | |
| Pharmaceutical Society of Great Britain | British pharmaceutical codex | |
| CN100500180C (en) | Pharmaceutical composition with expectorant, antitussive, antiasthmatic and antipyretic effects | |
| Foster | Reference-book of practical therapeutics | |
| CN101375851A (en) | Use of alkaloids compounds in preparing medicament for treating cough | |
| Paunikar et al. | A Textbook of Pharmacology-III |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190212 |